Volume : 13, Issue : 08, August – 2026

Title:

FORMULATION, DEVELOPMENT AND IN VITRO EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF VILDAGLIPTIN

Authors :

Kashaboina Anjali*, Mr. M. Sunil

Abstract :

The main aim of present work was to formulate and evaluate sustain release matrix tablets of Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Sustain release formulation are those which delivers the drug locally or systemically at a predetermined rate for a fixed period of time. The matrix tablet was prepared by direct compression method using by various concentration of Sodium CMC, Acacia and Tragacanth various release retardant polymer. The powder mixtures were subjected to various pre-compression parameters such as angle of repose, bulk density, tapped density and Carr’s index shows satisfactory result and the compressed tablets are evaluated for post-compression parameters such as weight variation, thickness, hardness, friability, drug content, in-vitro dissolution studies. In-vitro dissolution studies were carried out for 12 hours using 0.1 N HCL for first 2 hours and pH 6.8 phosphate buffer for 12 hours and the result showed that formulations V3 showed good dissolution profile to control the drug release respectively. Formulation containing higher concentration of Sodium CMC polymer sustained the drug release for the period of 12 hours. The kinetics studies the optimized formulation followed Zero order release kinetics.
Keywords: Vildagliptin, Sodium CMC, Acacia, Tragacanth, Direct compression and Sustained release matrix tablets.

Cite This Article:

Please cite this article in press Kashaboina Anjali et al., Formulation, development and in vitro evaluation of sustained release matrix tablets of Vildagliptin. Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. N. G. Raghavendra Rao, K. Richard Prasanna Raj, B. Sanjeev Nayak. Review on Matrix Tablet as Sustained Release. Volume 2, Issue 3 (2013),1-17.
2. Tarun Parashar,Soniya, Vishal Singh, Gaurav Singh, Satyanand Tyagi, Chirag Patel, Anil Gupta. Novel Oral Sustained Release Technology: A Concise Review.
2. Sudhir Karna, Shashank Chaturvedi, Vipin Agrawal, Mohammad Alim. Formulation Approaches For Sustained Release Dosage Forms: A Review. Asian J Pharm Clin Res, Vol 8, Issue 5, 2015, 46-53.
3. C.nithya shanthi, rakesh gupta, arun kumar mahato. A review on captopril oral sustained/controlled release Formulations. Int.J.Drug Dev. & Res., April-June 2010, 2(2): 257-267.
4. Rakesh Roshan Mali, Vaishali Goel, Sparsh Gupta. Novel Study in Sustained Release Drug Delivery System: A Review. Int. J. Pharm. Med. Res. 2015; 3(2):204-215.
5. Abhijeet Welankiwar. Review: Sustained Release Dosage Forms .
6. Lilesh khalane, atul alkunte, arunadevi birajdar. Sustained Release Drug Delivery System : A Concise Review.
7. Piyush Mandhar , Gayitri Joshi. Development of Sustained Release Drug Delivery System: A Review. Asian Pac. J. Health Sci., 2015; 2(1): 179-185.
8. H.D.Zalte, R.B.Saudagar. Review On Sustained Release Matrix Tablet. IJPBS -Volume 3- Issue 4 -OCT-DEC-2013-17-29.
9. Heena Farooqui and Prashant Upadhyay. Formulation And Evaluation Of Sustained-Release Tablet Having Genistein. IJPSR, 2022; Vol. 13(2): 810-820.
10. Lateef Gbenga Bakre, Emmanuel Akinyele, Oluyemisi Bamiro, Olutayo Adeleye, Olobayo Kunle. Formulation and Evaluation of Sustained Release Ibuprofen Matrix Tablets Using Starch from Maize Genotypes as Polymer. Seria Medica 2021;67(2):122-126.

Volume : 13, Issue : 08, August – 2026

Title:

EVALUATION OF ANTIHYPERLIPIDEMIC ACTIVITY OF SAPINDUS EMARGINATUS IN RATS

Authors :

Chinthala Jamima*, Dr.R.narasimha Rao, Dr.N. Raghunandhan

Abstract :

Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Sapindus emarginatus against hyperlipidemia. In this model of Hyperlipidemia, 30 adult male wistar rats (200-250gms) were evenly divided into 5 groups in both groups. Group-1 and Group-2 served as untreated and model controls respectively, while Group-3, 4 and 5 were the treatments groups which were simultaneously treated with standard, 100 and 200 mg/kg extract respectively along with High Fat Diet. On last day, blood samples for biochemical parameters, were obtained under inhaled diether anaesthesia. The outcomes of this study were expressed as mean standard error and data were evaluated by using analysis of variance followed by multiple comparisons. Oral administration of 100 mg/ kg and 200mg/kg body weight of Methanolic extract residual fraction of Moringa oleifera. Leaves exhibited a significant reduction (P < 0.01) in serum lipid parameters such as triglycerides, total cholesterol, low density lipoprotein (LDL), very LDL and increase in high density lipoprotein in hyperlipidemic rats when compared with hyperlipidemic control in both models. Our results demonstrated that Methanolic extract fraction of Sesbania grandiflora. Possessed significant antihyperlipidemic activity.
Keywords: Sesbania grandiflora, Cholesterol, LDL, triglycerides and antihyperlipidemic activity.

Cite This Article:

Please cite this article in press Chinthala Jamimaet al., Evaluation of Antihyperlipidemic activity of Sapindus Emarginatus in rats,, Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Amit G, Vandana S, Sidharth M. HYPERLIPIDEMIA: An Updated Review. Inter J of Biopharma & Toxicol Res 2011;1:81-89.
2. Virchow RP, Thrombose IG. In Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt-am-Main, Meidinger Sohn & Company 1856, S 458-564.
3. Ankur rohilla, Nidhi Dagar, Seema Rohilla, Amarjeet Dahiya, Ashok Kushnoor. HYPERLIPIDEMIA- a deadly pathological condition. Inter J Curr Pharma Res 2012;4:15-18
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-77.
5. Grundy SM, Vega GL. Hypertriglyceridemia: causes and relation to coronary heart disease – Semin. Thromb. Hemost 1988;14:249-64.
6. Dargel R. Lipoproteins and the etiopathogenesis of atherosclerosis. Zentralbl Allg Pathol 1989; 135: 501-504.